Clinical Orthopedics, Department of Clinical and Molecular Science, School of Medicine, Università Politecnica delle Marche, via Tronto 10/A, 60126, Torrette di Ancona, Italy.
Int Orthop. 2020 Jul;44(7):1287-1294. doi: 10.1007/s00264-020-04628-4. Epub 2020 Jun 1.
Core decompression is a surgical option since the 1960s for hip osteonecrosis treatment. This technique promotes bone repair by reducing intramedullary pressure, but this is not often enough to stop the progression of necrosis. The aim of this study was to associate core decompression with the regenerative stimulus provided by platelet-rich plasma (PRP) and compare our results with other regenerative techniques.
Femoral head osteonecrosis was prospectively evaluated in 30 hips (22 patients, 15-60 years) treated by core decompression and PRP graft. Patients presented monolateral or bilateral osteonecrosis in stage I-IIA-IIB according to Arlet and Ficat classification. The outcome was assessed by changes in Harris Hip Score (HHS) and the need for total hip replacement (THA).
The mean preoperative HHS was 64 points, at two years from surgery was roughly 84 points. Sixteen of 30 hips showed osteonecrosis progression of the femoral head and were converted to THA. At the five year follow-up, the survival rate was 100% for patients at stage I, 67% for stage IIA, and 0% for stage IIB and was 68% and 32% for idiopathic and secondary osteonecrosis, respectively.
Core decompression combined with PRP could be indicated as a treatment for the I and IIA stages of osteonecrosis, as it significantly reduces joint pain and delays THA. This procedure should be avoided in AVNFH related to cortisone therapy because only a few benefits have been proven. It also has the advantage of being technically simple, minimally invasive, and free from complications.
自 20 世纪 60 年代以来,核心减压一直是治疗股骨头坏死的一种手术选择。该技术通过降低髓内压来促进骨修复,但这通常不足以阻止坏死的进展。本研究的目的是将核心减压与富含血小板的血浆(PRP)提供的再生刺激相结合,并将我们的结果与其他再生技术进行比较。
前瞻性评估了 30 髋(22 例,15-60 岁)接受核心减压和 PRP 移植物治疗的股骨头坏死患者。患者根据 Arlet 和 Ficat 分类,单侧或双侧处于 I 期-IIA-IIB 期的骨坏死。通过 Harris 髋关节评分(HHS)的变化和全髋关节置换(THA)的需要来评估结果。
30 髋中,术前 HHS 平均为 64 分,术后 2 年约为 84 分。30 髋中有 16 髋出现股骨头坏死进展,转为 THA。5 年随访时,I 期患者的生存率为 100%,IIA 期为 67%,IIB 期为 0%,特发性和继发性骨坏死的生存率分别为 68%和 32%。
核心减压联合 PRP 可作为治疗 I 期和 IIA 期骨坏死的一种方法,因为它可以显著减轻关节疼痛并延迟 THA。对于与皮质激素治疗相关的 AVNFH,应避免使用该程序,因为只有少数益处得到证实。它还具有技术简单、微创和无并发症的优点。